YAP1 and macular degeneration: This approach identified verteporfin, a Food and Drug Administration (FDA)-approved member of the porphyrin family historically used as a photosensitiser to treat macular degeneration [216], to also act as an inhibitor of YAP–TEAD transcription, which selectively inhibited tumour growth in murine models of YAP-driven hepatocellular carcinoma [217].